Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 27, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on September 23, 2005, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 20,215 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on September 26, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses the notification of the share transfer in accordance with Disclosure Rule 3.1.4R(1)(b).
Important Facts for Investors
- The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
- Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold an interest in the shares held in the GSK Trust in the same capacity as other employees.
- The transaction involved the transfer of 20,215 Ordinary Shares to employee plan participants.
- This filing does not include quarterly or annual financial results.